article thumbnail

New European monograph for Cannabis flower adopted

European Pharmaceutical Review

.” Implementing quality standards for medicinal cannabis Mikael Sodergren of Curaleaf International explained in an article published on EPR’s website last month: “there is a vast range of flavonoids, terpenoids, phytols and other compounds present at lower concentrations within the cannabis flower”.

article thumbnail

Intelligent Automation in Pharmaceutical Industry (AI & ML)

PharmaShots

The article focuses on the integration of automation with Artificial Intelligence (AI) and Machine Learning (ML). This article provides an informative account of intelligent automation, the key differences between AI & ML, their importance, and a potent eight-step roadmap to implementation. With the impelling Pharma 4.0,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Adapting Customer Engagement Strategies to the COVID Landscape

Pharma Marketing Network

In office/in person sales promotion, the staple of pharmaceutical company activities, is simply not possible today with interactions reduced to the sporadic video or to telephone engagement. This will result in permanent shifts in how HCPs and patients interact with pharmaceutical companies.

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 134
article thumbnail

Why Home Remedies Deserve Respect

The People's Pharmacy

Before there were pharmaceutical companies, drug commercials on television, pharmacists or physicians, there were herbs and home remedies. In reality, when home remedies work, pharmaceutical companies usually figure out why. Then they isolate the compounds that provide benefit. This is irresponsible.

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. As covered in a previous article , the importance of R&D to develop treatments for rare diseases is high.

article thumbnail

A history of Pfizer

pharmaphorum

It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.